Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Merit Financial Group LLC

Merit Financial Group LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 56.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,024 shares of the biopharmaceutical company's stock after selling 25,473 shares during the quarter. Merit Financial Group LLC's holdings in Bristol-Myers Squibb were worth $1,027,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at about $25,000. Milestone Investment Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC lifted its holdings in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 200 shares in the last quarter. Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $40,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. StockNews.com lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Monday, April 15th. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating on the stock in a research note on Friday, April 26th. Barclays decreased their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating for the company in a research note on Friday, April 26th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a report on Thursday, April 18th. Finally, Societe Generale lowered Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $0.09 on Monday, hitting $43.90. The company's stock had a trading volume of 9,110,922 shares, compared to its average volume of 15,839,226. Bristol-Myers Squibb has a 1 year low of $43.33 and a 1 year high of $69.10. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a market cap of $88.99 billion, a price-to-earnings ratio of -14.16, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45. The firm has a 50 day moving average of $50.24 and a two-hundred day moving average of $50.57.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business's quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 earnings per share. Equities analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.47%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.